Physician profile
Keith A Friedenberg
NPI 1104928043
$123,673.82
in general payments reported to CMS, 2019-2025
53 companies · $23K in 2025
The $23K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $6,979 · 2021: $534 · 2022: $8,806 · 2023: $6,312 · 2024: $45K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Food and Beverage: $8,498 · Consulting Fee: $4,088 · Travel and Lodging: $2,622 · Honoraria: $1,505 · Education: $17.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,512.50 |
| Food and Beverage | $8,497.50 |
| Consulting Fee | $4,087.50 |
| Travel and Lodging | $2,622.14 |
| Honoraria | $1,505.00 |
| Education | $17.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $64,806.11 | 2024-2025 | Voquezna |
| Pfizer INC. | $29,220.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $10,560.82 | 2022-2023 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $5,672.80 | 2019 | |
| Celgene Corporation | $2,770.19 | 2020-2024 | Zeposia |
| Abbvie INC. | $2,244.87 | 2019-2025 | |
| Eli Lilly and Company | $1,738.11 | 2019-2020 | |
| Redhill Biopharma INC. | $1,505.31 | 2020 | |
| Janssen Biotech, INC. | $785.07 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $457.75 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $380.18 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Aimmune Therapeutics, INC. | $367.70 | 2023-2025 | Vowst |
| Gilead Sciences, INC. | $361.38 | 2019-2025 | |
| Vivus LLC | $227.06 | 2019-2025 | Qsymia |
| Regeneron Healthcare Solutions, INC. | $226.87 | 2022-2025 | Dupixent |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $215.80 | 2019-2024 | Dificid |
| Ardelyx, INC. | $200.16 | 2022-2024 | Ibsrela |
| Genzyme Corporation | $194.25 | 2022-2025 | |
| Qol Medical, LLC | $159.56 | 2022-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $152.25 | 2021-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $132.89 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $130.61 | 2024-2025 | Iqirvo, Bylvay |
| Adare Pharmaceuticals, INC. | $130.28 | 2019 | |
| Evoke Pharma, INC. | $114.21 | 2022-2025 | Gimoti |
| Lilly USA, LLC | $112.79 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $90.31 | 2021-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $76.27 | 2022-2025 | Rebyota |
| Novo Nordisk INC | $72.06 | 2022-2025 | Wegovy |
| Organon LLC | $68.39 | 2023-2024 | Hadlima, Renflexis |
| Shionogi INC | $68.33 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $63.71 | 2023 | Idacio |
| Concordia Pharmaceuticals INC. | $59.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.50 | 2023-2024 | Cyltezo |
| Amgen INC. | $51.85 | 2022-2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $39.37 | 2023 | Suflave, Sutab |
| Celltrion USA INC. | $35.45 | 2024-2025 | Vegzelma, Zymfentra |
| Sandoz INC. | $33.20 | 2025 | Hyrimoz |
| Shire North American Group INC | $24.76 | 2019 | |
| Caris Mpi, INC. | $22.22 | 2025 | Mi Cancer Seek |
| Romark Laboratories, Lc | $18.94 | 2019 | |
| Daiichi Sankyo INC. | $18.19 | 2023 | Injectafer |
| Allergan, INC. | $11.39 | 2019 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Friedenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.